abstract |
The present invention provides a novel means for treating and diagnosing endometriosis and endometrial cancer. The present invention provides an EG-VEGF polypeptide, a prokineticin 2 polypeptide, an EG-VEGF nucleic acid, for the treatment and diagnosis of endometriosis and endometrial cancer, and for the treatment of irregular bleeding. It relates to the pharmaceutical use of an effector or corresponding receptor of a prokineticin 2 nucleic acid. The invention further relates to measuring the amount of EG-VEGF, prokineticin 2 or EG-VEGF / prokineticin 2 receptor to diagnose receptivity. [Selection diagram] None |